This HTML5 document contains 162 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/
n9http://dx.doi.org/10.1128/

Statements

Subject Item
wd:Q39099424
rdf:type
wikibase:Item
schema:description
tieteellinen artikkeli наукова стаття, опублікована в червні 2017 videnskabelig artikel artigo científico bài báo khoa học 2017年论文 2017年の論文 article científic article scientific scientific article published on 19 June 2017 2017年論文 2017年论文 научни чланак articol științific научни чланак wissenschaftlicher Artikel artikel ilmiah 2017年论文 2017年论文 teaduslik artikkel scientific article published on 19 June 2017 vedecký článok 2017 nî lūn-bûn artikulong pang-agham tudományos cikk научная статья scientific article published on 19 June 2017 บทความทางวิทยาศาสตร์ article scientifique מאמר מדעי мақолаи илмӣ مقالة علمية نشرت في 19 يونيو 2017 wetenschappelijk artikel naučni članak 2017年論文 2017年论文 artículu científicu espublizáu en 2017 2017年論文 bilimsel makale 2017년 논문 artigo científico vitskapeleg artikkel სამეცნიერო სტატია artikull shkencor 2017年論文 научна статия articolo scientifico 2017年論文 vetenskaplig artikel artykuł naukowy artigo científico 2017年论文 επιστημονικό άρθρο ১৯ জুন ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ vitenskapelig artikkel scienca artikolo vědecký článek artículo científico publicado en 2017
p:P577
wds:Q39099424-D9D9F218-28C7-433D-9FCE-BB03DA0FD047
wdt:P577
2017-06-19T00:00:00Z
p:P407
wds:Q39099424-C9CB6C17-A303-449C-89C8-B9ABB65ED6A6
wdt:P407
wd:Q1860
p:P2860
wds:Q39099424-6FC4C77C-5415-4236-869F-4413BC9673FD wds:Q39099424-72794D20-3900-4576-989E-53174E5F5CEE wds:Q39099424-734A0CA5-3A61-4DED-9833-D2F4CCB41805 wds:Q39099424-51118A14-7E8E-48CD-8BDE-13825909416D wds:Q39099424-5551C53B-8357-4AD9-A1D2-5C9384027FAB wds:Q39099424-5AC816BE-5AEF-4167-B648-F08377291DE7 wds:Q39099424-1F5D7885-059A-429A-94AA-C26817D0335E wds:Q39099424-23A0254C-48DF-47A1-9B78-D7DA294CAD20 wds:Q39099424-44D105A1-91AA-4CC7-84FA-A3E4CF072270 wds:Q39099424-0F63C617-DBA9-4133-87F6-49D0FEDE7237 wds:Q39099424-1A9E70F0-EA44-4F46-9567-C1331A2B19F4 wds:Q39099424-B4646892-826C-4389-9DB2-2BD1B307E370 wds:Q39099424-9F023EFE-7E04-4195-84FC-6288B52F3C79 wds:Q39099424-AA1C3601-C66A-48DD-A1D1-3E56926B942F wds:Q39099424-927BE681-7D9F-4BDF-97B2-ECD0E882A8CA wds:Q39099424-99AD050D-799E-474B-8DE4-25CA17C19CB3 wds:Q39099424-9A248DD1-8892-47EB-B4F8-35CD94A4FDBA wds:Q39099424-7668CB8E-DB3E-48C2-B372-5EFCC04D0675 wds:Q39099424-806BC5FC-719C-4FD3-9C2D-3C58561465F1 wds:Q39099424-FD22EBCB-CFD3-47AC-A02E-4AF8344FB57A wds:Q39099424-D1D242B8-E5CF-4042-9169-D2FEB105F9F2 wds:Q39099424-E4739630-90D6-40C4-9E90-B870C4627D18 wds:Q39099424-F2E8721A-3E96-4F9A-9ED0-81CE9C0FA45B wds:Q39099424-BF40F836-408E-4577-92F6-0586104BF0AC wds:Q39099424-D16533EC-E4A1-489E-B2C0-E2F4AF80B173 wds:Q39099424-01D045B8-01E7-4162-8A8F-0F84C9E80FE3
wdt:P2860
wd:Q35857069 wd:Q37383298 wd:Q37444728 wd:Q41866966 wd:Q40098763 wd:Q40707426 wd:Q41916570 wd:Q37383289 wd:Q41930012 wd:Q21034131 wd:Q35906361 wd:Q47824906 wd:Q35834996 wd:Q40394062 wd:Q43681442 wd:Q44624153 wd:Q33738084 wd:Q39121208 wd:Q43938179 wd:Q38895510 wd:Q35166991 wd:Q39182052 wd:Q40271385 wd:Q37356688 wd:Q26783646 wd:Q33978975
p:P2093
wds:Q39099424-C5D96691-FB49-46F9-9968-3613415ABF70 wds:Q39099424-794DAD1F-A24F-47DB-A8A2-1C56F16C01B0 wds:Q39099424-760B71EF-9752-4880-BDD9-4E2D11CCB645 wds:Q39099424-68D7B059-99AB-4724-B1A5-CF071D3CE123 wds:Q39099424-41609977-6387-420F-B6D7-8BD1DA30AF63 wds:Q39099424-083AA733-29BE-480C-B62A-C446F331DA1E wds:Q39099424-FAE3EE8A-AB48-42CE-AA8E-D387D23C7EA1 wds:Q39099424-F4961FD5-89BD-4EE9-A21E-06037B500CA6 wds:Q39099424-F8BFB491-3A0D-4883-A494-3E1795A68EE3
wdt:P2093
Vishal Koradia Sampath Kalluri Marie-Christine Wolf Jay Prakash Jain Lan Chen Gangadhar Sunkara Daniel S Stein F Joel Leong Jagannath Kota
rdfs:label
Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers
skos:prefLabel
Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers
schema:name
Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers
p:P1476
wds:Q39099424-B3C6F42A-3BE4-472B-AB0A-69E9A9810D8F
wdt:P1476
Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers
p:P31
wds:Q39099424-4B87A5DF-791B-4FF3-AE43-F119BC27EFE7
wdt:P31
wd:Q13442814
p:P921
wds:Q39099424-ACE38F3D-523E-417F-B59F-E524B00B3CED
wdt:P921
wd:Q904464
p:P698
wds:Q39099424-BDA47245-EE43-4F42-BA33-D6B5F992203F
wdtn:P698
n12:28630183
wdt:P698
28630183
p:P1433
wds:Q39099424-9E85466D-B634-4081-8B83-EE4DB956D43B
wdt:P1433
wd:Q578004
p:P433
wds:Q39099424-8F5154F1-D572-4664-B6FD-58A37D528044
p:P478
wds:Q39099424-10ED8B9D-6EB5-4F8B-8708-325326B3999B
wdt:P433
9
wdt:P478
61
p:P356
wds:Q39099424-A007D7CB-6657-4B4C-980C-1C3C61923C37
wdtn:P356
n9:AAC.00868-17
wdt:P356
10.1128/AAC.00868-17
p:P932
wds:Q39099424-176A3FE8-2DA0-49C1-B9F2-68890E981DED
wdt:P932
5571342